tweetindex
FR

Regeneron

@Regeneron · Tarrytown, NY · joined 06 Mar 2009

Official channel for Regeneron. We turn science into medicine for people with serious diseases. View our terms of engagement here: https://t.co/EuFDUdQQ5E

33 856Followers
254Following
5 203Posts total
16.1KViews on collected posts

Derniers posts

@Regeneron Gratidão por ajudar o @avioesemusicas . 28 views · 2 likes · 0 reposts · 0 replies Open on X →
@Regeneron Obrigada pelo remédio do @avioesemusicas !! 29 views · 1 likes · 1 reposts · 0 replies Open on X →
@Regeneron @Regeneron Muito Obrigado por enviarem o medicamento para o @avioesemusicas 33 views · 2 likes · 0 reposts · 0 replies Open on X →
#BreakingNews: The U.S. FDA approved our medicine to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP) – an ultra-rare genetic disorder. Read more: https://t.co/Xu5t4medMA http
0:20
5.5K views · 29 likes · 6 reposts · 6 replies Open on X →
Join us in celebrating the 2026 Regeneron Prize for Creative Innovation winners — early-career scientists honored for their bold 'dream project; proposals in biomedical research. Meet this year’s winners. 👉 https://t.co/BDUPtc7xnI https://t.co/de3gKCLNez
2026 Regeneron Prize Winners
Siyuan Du, Ph.D. Stanford | Graduate Winner Dream Project: using cryo-ET technology to map the structure and function of heterchromatin
Frank Peters RPI | Graduate Winner Dream Project: using 3D-printing of vascular organoids to study intact vascular networks
1.2K views · 5 likes · 1 reposts · 0 replies Open on X →
Today, we announced second quarter 2026 financial and operating results, reflecting a strong quarter of pipeline progress, commercial momentum and continued impact for people around the world. Read more: https://t.co/PqBcYaa1OI https://t.co/OpxTfnD7ft
2026 second quarter financial and operating results
$4.3B revenues in Q2 2026 increasing 17% versus Q2 '25
"Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline. With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases." Leonard Schleifer, MD, PhD Board co-Chair, President and Chief Executive Officer
"Given Regeneron's strong financial position, we continue to invest confidently in our pipeline, U.S. manufacturing, and external innovation, while returning capital to shareholders." Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer
1.4K views · 7 likes · 1 reposts · 0 replies Open on X →
We're pleased to announce that regulatory submissions have been accepted for review by the U.S. FDA and EMA for our novel siRNA investigational medicine for adult patients with generalized myasthenia gravis (#gMG). Read more: https://t.co/q9K5nzHGWx https://t.co/BUpVbZrzez
6.8K views · 23 likes · 2 reposts · 0 replies Open on X →
Great music and great science demand practice and precision, and we follow the science by letting data set the tempo. This June, our teams share new work in two major music cities. Learn more about our latest advancements: https://t.co/LCy5n1FCuo https://t.co/Q4DtxzX1oS
1.2K views · 4 likes · 1 reposts · 0 replies Open on X →

Face aux comptes de taille comparable

5 posts des 90 derniers jours, à côté de la tranche de 10K–100K abonnés. touche moins de monde que ses pairs, mais les engage bien davantage.

Vues médianes33ce compte924médiane pour 10K–100K
Portée, %0.10%ce compte3.62%médiane pour 10K–100K
Engagement, %6.06%ce compte1.52%médiane pour 10K–100K
IndicateurCe compteMédiane pour 10K–100KRapport
Vues médianes par post339240.04×
Portée (vues ÷ abonnés)0.10%3.62%0.03×
Taux d'engagement6.06%1.52%3.98×

Autres comptes de cette tranche →   Comparer avec un autre compte →   Comment ces repères sont établis →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

1.2K4 Jun
6.8K22 Jun
1.4K30 Jul
1.2K31 Jul
5.5K19 Aug
3315 Sep
29
28

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.41%4 Jun
0.39%22 Jun
0.57%30 Jul
0.49%31 Jul
0.81%19 Aug
6.06%15 Sep
6.90%
7.14%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes73.7%73 in total
Reposts12.1%12 in total
Replies6.1%6 in total
Quotes4.0%4 in total
Bookmarks4.0%4 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Comptes similaires